Table 3. VUD recipients . N, 3y .... | American Society of Hematology

Table 3.

VUD recipients

	N, 3y	Survival, %	LFS, %	Relapse, %	TRM, %
Total	58	57	50	15	35
Stage
CP1	47	65	56	13	31
No CP1	11	39	34	20	46
Sex mismatch
Male/female	13	46	40	17	44
Other combinations	45	62	53	15	32
CMV status, R/D
+/+	22	64	52	17	31
-/+	9	40	33	15	52
+/-	7	89	67	21	11
-/-	14	54	52	12	36
IFN
No	23	57	46	22	32
Yes	21	51	42	12	45
TBI
No	5	68	68	0	32
Yes	53	57	48	17	35
Acute GVHD
TCD+/- CSA/MTX	38	53	43	18	39
CSA + MTX	20	69	64	10	26
TCD
No	20	67	62	10	28
Yes	38	53	43	18	39
Interval diagnosis to SCT, mo
0-6	8	54	49	18	33
6-12	13	52	50	14	36
Longer than 12	37	62	50	15	35

	N, 3y	Survival, %	LFS, %	Relapse, %	TRM, %
Total	58	57	50	15	35
Stage
CP1	47	65	56	13	31
No CP1	11	39	34	20	46
Sex mismatch
Male/female	13	46	40	17	44
Other combinations	45	62	53	15	32
CMV status, R/D
+/+	22	64	52	17	31
-/+	9	40	33	15	52
+/-	7	89	67	21	11
-/-	14	54	52	12	36
IFN
No	23	57	46	22	32
Yes	21	51	42	12	45
TBI
No	5	68	68	0	32
Yes	53	57	48	17	35
Acute GVHD
TCD+/- CSA/MTX	38	53	43	18	39
CSA + MTX	20	69	64	10	26
TCD
No	20	67	62	10	28
Yes	38	53	43	18	39
Interval diagnosis to SCT, mo
0-6	8	54	49	18	33
6-12	13	52	50	14	36
Longer than 12	37	62	50	15	35

Data reflect survival and LFS Kaplan-Meier estimated probabilities and relapse and TRM cumulative incidence estimates at 3 years.

N, 3 y indicates number of patients at risk at 3 years.